Biotech
Pharma
CRO/CMO/CDMO
Medtech
Bioinformatics
Advisor
KJ Wang
KJ brings extensive hands-on experience in biopharma, equity research, and investment banking to QIC, focusing on value creation in the healthcare industry. During his 11-year tenure at QIC, KJ facilitated more than 30 corporations in raising their profile as investment opportunities, allowing investors to evaluate and make informed decisions. Key accounts include PharmaEssentia, Oneness Biotech, Foresee Pharmaceuticals, Polaris Pharmaceuticals, Adimmune, Senhwa Biosciences, Coland Holdings, Chlitina, and CHC Group.
KJ and his team help companies identify suitable investors. They introduce companies to those investors on global non-deal roadshows and at conferences. He and the team also assist in fundraising and mergers and acquisitions. When necessary and appropriate, they help place stock, improve liquidity, and translate clients' ESG efforts to improved ratings.
Advisor
Allan Chen
Allan is a Research Analyst at QIC, specializing in the Technology Hardware, Healthcare, Biotech, and Pharmaceutical sectors. In this role, he conducts deep-dive industry research, financial modeling, and investment due diligence to support strategic decision-making for both clients and internal teams.
At QIC, He is responsible for developing in-depth equity and sector reports, supporting capital market communications, and evaluating investment opportunities across public and private markets. Allan's research focuses on identifying key growth drivers, market dynamics, and valuation inflection points, with a particular emphasis on innovative healthcare solutions and emerging technologies.
Advisor
KJ Wang
KJ brings extensive hands-on experience in biopharma, equity research, and investment banking to QIC, focusing on value creation in the healthcare industry. During his 11-year tenure at QIC, KJ facilitated more than 30 corporations in raising their profile as investment opportunities, allowing investors to evaluate and make informed decisions. Key accounts include PharmaEssentia, Oneness Biotech, Foresee Pharmaceuticals, Polaris Pharmaceuticals, Adimmune, Senhwa Biosciences, Coland Holdings, Chlitina, and CHC Group.
KJ and his team help companies identify suitable investors. They introduce companies to those investors on global non-deal roadshows and at conferences. He and the team also assist in fundraising and mergers and acquisitions. When necessary and appropriate, they help place stock, improve liquidity, and translate clients' ESG efforts to improved ratings.
Advisor
Allan Chen
Allan is a Research Analyst at QIC, specializing in the Technology Hardware, Healthcare, Biotech, and Pharmaceutical sectors. In this role, he conducts deep-dive industry research, financial modeling, and investment due diligence to support strategic decision-making for both clients and internal teams.
At QIC, He is responsible for developing in-depth equity and sector reports, supporting capital market communications, and evaluating investment opportunities across public and private markets. Allan's research focuses on identifying key growth drivers, market dynamics, and valuation inflection points, with a particular emphasis on innovative healthcare solutions and emerging technologies.
Clients
聯絡我們
有任何疑問或合作需求，歡迎隨時與我們聯絡。